Mepivacaína Physan (Mepivacaine Hydrochloride)

Mepivacaine is used to provide local anesthesia in various procedural settings.

• Epidural analgesia: provides regional pain relief during labor, childbirth or abdominal surgery.
• Infiltration anesthesia for minor surgical procedures: numbs the specific tissue area to allow painless incision and suturing.
• Intrapleural analgesia: reduces pain after thoracic interventions by anesthetizing the pleural surface.
• Dental procedures requiring local anesthesia: enables pain‑free dental extractions, restorations and periodontal work.

• Mepivacaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the influx of sodium ions required for depolarization. By inhibiting the initiation and propagation of nerve impulses, it produces a reversible loss of sensation in the administered area, allowing temporary analgesia and muscle relaxation during procedures.

Mepivacaine may cause a range of adverse reactions, most of which are related to its local anesthetic properties.

Common Side Effects

• Tingling or numbness at the injection site.
• Mild dizziness or light‑headedness.
• Transient headache.
• Localized swelling or bruising.
• Temporary increase in heart rate.
• Mild nausea.

Serious or Rare Side Effects

• Allergic reaction such as rash, itching or anaphylaxis.
• Cardiovascular collapse or severe hypotension.
• Central nervous system toxicity presenting as seizures or loss of consciousness.
• Prolonged numbness beyond the expected duration.
• Methemoglobinemia.
• Cardiac arrhythmias.

When using Mepivacaína Physan, clinicians should consider several safety measures.

• Patient assessment: evaluate cardiac, hepatic and renal function before administration.
• Dose limitation: avoid exceeding recommended maximum doses for the specific route.
• Monitoring: observe vital signs and neurological status during and after injection.
• Contraindications: do not use in patients with known hypersensitivity to amide‑type local anesthetics.
• Drug interactions: review concomitant medications that may affect cardiac conduction.
• Store at ambient temperature: keep below 25°C, protect from light and moisture, and retain in original packaging.

Mepivacaína Physan can interact with other agents that influence cardiac conduction or central nervous system activity.

Major Interactions (Avoid)

• Class I anti‑arrhythmic drugs (e.g., quinidine, procainamide) – may potentiate cardiotoxicity.
• Monoamine oxidase inhibitors – increase risk of hypertensive crisis.
• High‑dose beta‑blockers – can exacerbate bradycardia.

Moderate Interactions (Monitor Closely)

• Other local anesthetics – cumulative toxicity risk.
• CNS depressants (e.g., benzodiazepines, opioids) – may enhance sedation.
• Diuretics – may alter plasma protein binding and affect drug levels.